Treatment | Genotypes classes | CR + PR (%) | NC + PD (%) | P value | Duration of treatment, months | P value | TTF1/TNT2
months | P value | OS months | P value |
---|
Cyclophosphamide |
CYP2C19
| | | | | | | | | |
| EM vs. | 164 (78) | 46 (22) | 0.7 | NR | NR | 28.7 | 0.4 | 73.9 | 0.4 |
| IM + PM | 23 (75) | 14 (24) | | | | 25.1 |
(0.4)
| 65.6 |
(0.5)
|
Thalidomide
|
CYP2C19
| | | | | | | | | |
| EM vs. | 78 (62) | 48 (38) | 0.5 | 7.4 | 0.9 | 10.5 | 0.6 | 62.4 | 0.8 |
| IM + PM | 22 (53) | 18 (45) | | 7.0 | | 7.4 | | 65.6 | |
Bortezomib
|
CYP2C19
| | | | | | | | | |
| EM | 36 (73) | 13 (27) | 0.5 | 3.8 | 0.6 | 8.8 | 0.9 | 83.4 | 0.9 |
| IM + PM | 13 (27) | 3 (13) |
(0.3)
| |
(0.6)
| 7.8 |
(0.7)
| 74.0 |
(0.9)
|
|
CYP2D6
| | | | | | | | | |
| UM + EM | 21 (81) | 5 (19) | 1 | 4.2 | 0.8 | 7.8 | 0.07 | 69.7 | 0.12 |
| IM + PM | 16 (84) | 3 (16) |
(0.9)
| |
(0.9)
| 11.3 |
(0.2)
| 96.1 |
(0.2)
|
- NR, not relevant; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra rapid metabolizer;
- CR, complete response; PR, partial response; NC, no change; PD, progressive disease. TTF, time-to-treatment failure;
- TNT, time-to-next treatment
- 1) TTF is used for evaluation of efficacy of treatment with cyclophosphamide
- 2) TNT is used for evaluation of efficacy of treatment with thalidomide and bortezomib.
- For treatment with cyclophosphamide values in italics are adjusted for prognostic markers: TTF: β2-microglobulin; OS: β2-microglobulin, creatinine and Durie-Salmon stage. At relapse age was a prognostic marker. No influence of age was found for patients treated with thalidomide. For treatment with bortezomib values in italics are adjusted for age at start of relapse treatment and are shown in parentheses.